Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Zynex Announces June Orders | ||
| By: PR Newswire Association LLC. - 22 Jul 2016 | Back to overview list |
|
LONE TREE, Colo., July 22, 2016 /PRNewswire/ -- Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurodiagnostic equipment, cardiac and blood volume monitoring, announces today the amount of orders received in June for its electrotherapy product line. CEO, Thomas Sandgaard, said: "We processed 2,072 prescription orders for electrotherapy devices in June, a 123% increase or more than double of our order production in June of last year. It is at the same time a 12% decrease compared to May of this year, primarily caused by capital constraints that limit our ability to produce enough NexWave devices. We continue to see a huge unmet need for our devices and are working diligently to attract financing that will enable us to fill our orders timely and invest in inventory for our sales force. " About Zynex Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com. Safe Harbor Statement Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our compound pharmacy and international expansion efforts, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2015. Contact: Logo - http://photos.prnewswire.com/prnh/20160531/373722LOGO
SOURCE Zynex 
|
||
|
||
 | Back to overview list | |